Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for Severe COVID-19
NCT04273646Unknown
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, double-blind trial of human umbilical cord mesenchymal stem cells in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Pneumonia severity index at 12 weeks and Oxygenation index (PaO2/FiO2) at 12 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04273646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273646.